In year one of the multi-year deal, a minimum order volume of 20,000 units with an estimated value of at least $1.65 million will be supplied to Onix, which would increase in years two though seven to at least 50,000 units, worth $4.1 million per year, MGC Pharma said, noting that the deal may be renewed for an extra five-year term by mutual agreement.
The ASX junior said the amended deal, along with its current level of monthly sales in Australia, is expected to deliver the company break-even cashflow at the start of year two of the agreement. Positive EBITDA is forecast for the start of 202
Ann: March Quarterly Activity and Cashflow Report, page-2
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.0¢ |
Change
0.010(1.89%) |
Mkt cap ! $26.13M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 57.0¢ | 54.0¢ | $66.55K | 120.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 334 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 1767 | 1 |
View Market Depth
| Last trade - 15.52pm 02/10/2024 (20 minute delay) ? |
| RGT (ASX) Chart |